These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 16135267)

  • 1. Measles: prevention.
    Bedford H; Sengupta N; Elliman D; Booy R
    Clin Evid; 2005 Jun; (13):373-87. PubMed ID: 16135267
    [No Abstract]   [Full Text] [Related]  

  • 2. Measles (prevention).
    Bedford H; Sengupta N; Elliman D; Booy R
    Clin Evid; 2004 Jun; (11):436-51. PubMed ID: 15652014
    [No Abstract]   [Full Text] [Related]  

  • 3. Measles.
    Clin Evid; 2003 Jun; (9):396-406. PubMed ID: 15366148
    [No Abstract]   [Full Text] [Related]  

  • 4. Measles.
    Donald A; Muthu V
    Clin Evid; 2002 Jun; (7):331-40. PubMed ID: 12230657
    [No Abstract]   [Full Text] [Related]  

  • 5. Measles, mumps, and rubella: prevention.
    Booy R; Sengupta N; Bedford H; Elliman D
    Clin Evid; 2006 Jun; (15):448-68. PubMed ID: 16973018
    [No Abstract]   [Full Text] [Related]  

  • 6. Live attenuated measles and mumps viral strain-containing vaccines and hearing loss: Vaccine Adverse Event Reporting System (VAERS), United States, 1990--2003.
    Asatryan A; Pool V; Chen RT; Kohl KS; Davis RL; Iskander JK;
    Vaccine; 2008 Feb; 26(9):1166-72. PubMed ID: 18255204
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Potential impacts of schedule changes, waning immunity and vaccine uptake on measles elimination in Australia.
    Wood JG; Gidding HF; Heywood A; Macartney K; McIntyre PB; Macintyre CR
    Vaccine; 2009 Jan; 27(2):313-8. PubMed ID: 18977272
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prevalence of IgG antibody against measles, mumps and rubella in bangladeshi children: a pilot study to evaluate the need for integrated vaccination strategy.
    Sultana R; Rahman MM; Hassan Z; Hassan MS
    Scand J Immunol; 2006 Dec; 64(6):684-9. PubMed ID: 17083626
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of potentially common adverse events associated with the first and second doses of measles-mumps-rubella vaccine.
    LeBaron CW; Bi D; Sullivan BJ; Beck C; Gargiullo P
    Pediatrics; 2006 Oct; 118(4):1422-30. PubMed ID: 17015532
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immediate injection pain in infants aged 18 months during vaccination against measles, mumps and rubella with either Priorix or MMR-II.
    Knutsson N; Jansson UB; Alm B
    Vaccine; 2006 Jul; 24(31-32):5800-5. PubMed ID: 16765490
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Measles and human movement in Europe.
    Massad E
    J Travel Med; 2018 Jan; 25(1):. PubMed ID: 30312454
    [No Abstract]   [Full Text] [Related]  

  • 12. Getting it wrong.
    Wakefield AJ; Stott C; Krigsman A
    Arch Dis Child; 2008 Oct; 93(10):905-6; author reply 906-7. PubMed ID: 18809705
    [No Abstract]   [Full Text] [Related]  

  • 13. [Measles].
    Stock I
    Med Monatsschr Pharm; 2009 Apr; 32(4):118-26; quiz 127-8. PubMed ID: 19445268
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety and immunogenicity of a measles-mumps-rubella-varicella vaccine given as a second dose in children up to six years of age.
    Halperin SA; Ferrera G; Scheifele D; Predy G; Stella G; Cuccia M; Douha M; Willems P
    Vaccine; 2009 May; 27(20):2701-6. PubMed ID: 19428882
    [TBL] [Abstract][Full Text] [Related]  

  • 15. What does this study test, and why?
    Stone J
    Arch Dis Child; 2008 Oct; 93(10):905; author reply 906-7. PubMed ID: 18809706
    [No Abstract]   [Full Text] [Related]  

  • 16. Response to the article by Baird et al.
    Burn R
    Arch Dis Child; 2008 Oct; 93(10):905; author reply 906-7. PubMed ID: 18809707
    [No Abstract]   [Full Text] [Related]  

  • 17. Risk of immune thrombocytopenic purpura after measles-mumps-rubella immunization in children.
    France EK; Glanz J; Xu S; Hambidge S; Yamasaki K; Black SB; Marcy M; Mullooly JP; Jackson LA; Nordin J; Belongia EA; Hohman K; Chen RT; Davis R;
    Pediatrics; 2008 Mar; 121(3):e687-92. PubMed ID: 18310189
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunogenicity and safety of a second dose of measles-mumps-rubella-varicella vaccine in healthy children aged 5 to 6 years.
    Vesikari T; Baer M; Willems P
    Pediatr Infect Dis J; 2007 Feb; 26(2):153-8. PubMed ID: 17259879
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunogenicity and safety of measles-mumps-rubella-varicella (MMRV) vaccine followed by one dose of varicella vaccine in children aged 15 months-2 years or 2-6 years primed with measles-mumps-rubella (MMR) vaccine.
    Gillet Y; Steri GC; Behre U; Arsène JP; Lanse X; Helm K; Esposito S; Meister N; Desole MG; Douha M; Willems P
    Vaccine; 2009 Jan; 27(3):446-53. PubMed ID: 19007835
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Recent results in the immunological prevention of measles].
    Tacconi L; Cantalamessa Carboni L; Tarsitani G
    Nuovi Ann Ig Microbiol; 1984; 35(3):233-45. PubMed ID: 6536931
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.